Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lonza Group | BATS Europe | Healthcare | Biotechnology & Medical Research | €43.27B | 58x | €612.34 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
argenx SE | Vienna | Healthcare | Biotechnology & Medical Research | €30.30B | 32.5x | 0.08 | €484.10 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Argen-X | Brussels | Healthcare | Biotechnology & Medical Research | €30.30B | 32.5x | 0.08 | €494.50 | 1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 42% Upside | Upgrade to Pro+ | |
arGEN X BV | BATS Europe | Healthcare | Biotechnology & Medical Research | €30.23B | 32.4x | 0.08 | €481.20 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
argenx | Frankfurt | Healthcare | Biotechnology & Medical Research | €30.23B | 32.4x | 0.08 | €489.60 | 1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BioNTech SE | Xetra | Healthcare | Biotechnology & Medical Research | €23.84B | -30.2x | 0.04 | €96.95 | 2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biontech | Frankfurt | Healthcare | Biotechnology & Medical Research | €23.84B | -30.2x | 0.04 | €97.05 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BioNTech SE DRC | Vienna | Healthcare | Biotechnology & Medical Research | €23.84B | -30.2x | 0.04 | €97 | 2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
IQVIA Holdings | Milan | Healthcare | Biotechnology & Medical Research | €23.61B | 21.5x | 78.75 | €134.30 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
IQVIA Holdings | Vienna | Healthcare | Biotechnology & Medical Research | €23.61B | 21.5x | 78.75 | €133.85 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genmab AS | Vienna | Healthcare | Biotechnology & Medical Research | €11.76B | 77.6x | 0.04 | €190.10 | 1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genmab | BATS Europe | Healthcare | Biotechnology & Medical Research | €11.75B | 77.6x | 0.04 | €188.07 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Eurofins Scientific | BATS Europe | Healthcare | Biotechnology & Medical Research | €11.67B | 33.3x | 0.74 | €60.62 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Eurofins Scientific | Paris | Healthcare | Biotechnology & Medical Research | €11.67B | 33.3x | 0.74 | €60.54 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -8.9% Downside | Upgrade to Pro+ | |
Eurofins Scientific SE | Vienna | Healthcare | Biotechnology & Medical Research | €11.67B | 33.3x | 0.74 | €60.70 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Eurofins Scientific | Frankfurt | Healthcare | Biotechnology & Medical Research | €11.66B | 33.3x | 0.74 | €60.56 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Exelixis | Frankfurt | Healthcare | Biotechnology & Medical Research | €10.52B | 19.7x | 0.08 | €38.18 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ascendis Pharma | Frankfurt | Healthcare | Biotechnology & Medical Research | €9.14B | -24.6x | -0.78 | €150 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Qiagen NV | Milan | Healthcare | Biotechnology & Medical Research | €8.99B | 111.2x | -1.53 | €41.13 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Qiagen | Vienna | Healthcare | Biotechnology & Medical Research | €8.99B | 111.2x | -1.5 | €41.27 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Qiagen | Xetra | Healthcare | Biotechnology & Medical Research | €8.99B | 111.2x | -1.5 | €41.49 | 1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9.5% Upside | Upgrade to Pro+ | |
Qiagen NV | Frankfurt | Healthcare | Biotechnology & Medical Research | €8.99B | 111.2x | -1.51 | €41.39 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9.1% Upside | Upgrade to Pro+ | |
Qiagen NV | BATS Europe | Healthcare | Biotechnology & Medical Research | €8.97B | 111.2x | -1.54 | €41.15 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Blueprint Medicines | Frankfurt | Healthcare | Biotechnology & Medical Research | €7.20B | -52.8x | -1.12 | €109.50 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Ionis Pharmaceuticals | Frankfurt | Healthcare | Biotechnology & Medical Research | €5.86B | -14.2x | 1.21 | €36.57 | 2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merus NV | Frankfurt | Healthcare | Biotechnology & Medical Research | €3.62B | -13.6x | 0.29 | €47.60 | 2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BB Biotech | Xetra | Healthcare | Biotechnology & Medical Research | €1.93B | -4.3x | 0.02 | €35.30 | 2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BB Biotech | Frankfurt | Healthcare | Biotechnology & Medical Research | €1.93B | -4.3x | 0.02 | €35.25 | 3.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BB Biotech AG BATS | BATS Europe | Healthcare | Biotechnology & Medical Research | €1.92B | -4.3x | 0.02 | €35.36 | 1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Denali Therapeutics | Frankfurt | Healthcare | Biotechnology & Medical Research | €1.86B | -5.5x | 0.03 | €12.77 | 5.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genus | Frankfurt | Healthcare | Biotechnology & Medical Research | €1.83B | -399.7x | 3.84 | €27.80 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genus | BATS Europe | Healthcare | Biotechnology & Medical Research | €1.82B | -399.7x | 3.51 | €28 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Galapagos | BATS Europe | Healthcare | Biotechnology & Medical Research | €1.74B | -9.7x | 0.06 | €26.12 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Galapagos | Amsterdam | Healthcare | Biotechnology & Medical Research | €1.74B | -9.7x | 0.06 | €26.38 | 1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 28.8% Upside | Upgrade to Pro+ | |
Galapagos NV | Vienna | Healthcare | Biotechnology & Medical Research | €1.74B | -9.7x | 0.06 | €26.06 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Evotec AG | BATS Europe | Healthcare | Biotechnology & Medical Research | €1.30B | -6.4x | 0.05 | €7.15 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Evotec | Vienna | Healthcare | Biotechnology & Medical Research | €1.30B | -6.4x | 0.05 | €7.27 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Evotec | Frankfurt | Healthcare | Biotechnology & Medical Research | €1.30B | -6.3x | 0.05 | €7.27 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 30% Upside | Upgrade to Pro+ | |
Evotec SE | Milan | Healthcare | Biotechnology & Medical Research | €1.30B | -6.3x | 0.05 | €7.37 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Evotec AG | Xetra | Healthcare | Biotechnology & Medical Research | €1.30B | -6.3x | 0.05 | €7.32 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 29.7% Upside | Upgrade to Pro+ | |
Viridian Therapeutics | Frankfurt | Healthcare | Biotechnology & Medical Research | €1.18B | -5.1x | 0.38 | €14.22 | 3.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Intellia Therapeutics | Frankfurt | Healthcare | Biotechnology & Medical Research | €1.07B | -2.3x | -0.88 | €10.20 | -2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
CureVac NV | Xetra | Healthcare | Biotechnology & Medical Research | €1.06B | 5.8x | 0.04 | €4.67 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Curevac | Frankfurt | Healthcare | Biotechnology & Medical Research | €1.06B | 5.8x | 0.04 | €4.66 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
CureVac NV | Milan | Healthcare | Biotechnology & Medical Research | €1.06B | 5.8x | 0.04 | €4.65 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
CureVac NV | Vienna | Healthcare | Biotechnology & Medical Research | €1.06B | 5.8x | 0.04 | €4.64 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novavax | Frankfurt | Healthcare | Biotechnology & Medical Research | €970.05M | 2.3x | 0.01 | €5.95 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novavax | Vienna | Healthcare | Biotechnology & Medical Research | €970.05M | 2.3x | 0.01 | €5.91 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
CareDx | Frankfurt | Healthcare | Biotechnology & Medical Research | €920.25M | 16.7x | 0.12 | €16.36 | 1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Philogen SpA | Milan | Healthcare | Biotechnology & Medical Research | €919.57M | 18.8x | 0.02 | €22.80 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.8% Upside | Upgrade to Pro+ |